Home
Smart & Biggar
Urszula Wojtyra
Urszula Wojtyra
Smart & Biggar
2021 PMPRB Annual Report
01 Dec 2022 | Canada
PMPRB Finds Ultra-Rare Drug PROCYSBI Is Excessively Priced
31 Oct 2022 | Canada
Saskatchewan Launches Biosimilars Initiative
31 Oct 2022 | Canada
PM(NOC) Regulations: Five-year Anniversary Of Major Amendments
28 Sep 2022 | Canada
Health Canada Releases Its Health Product Highlights, Annual Drug Submission Performance Reports And OPML Statistical Report
01 Sep 2022 | Canada
Federal Court Finds Minister Of Health Reasonable In Concluding JAMP Not A ‘Second Person' For Its SIMLANDI Biosimilar
30 Aug 2022 | Canada
Final Report From Advisory Panel On Potential Pan-Canadian Formulary Is Released
01 Aug 2022 | Canada
Competition Bureau Closes Two Investigations Into Pharmaceutical Patent Litigation Settlements
29 Jul 2022 | Canada
Updates To Health Canada's Regulatory Initiatives For 2022-2024, And Amendments To Food And Drug Regulations (Exports And Transhipments Of Drugs)
30 Jun 2022 | Canada
Update On Biosimilars In Canada – June 2022
30 Jun 2022 | Canada
New Guidance Documents And Regulatory Amendments Regarding Therapeutic Product Shortages
31 Mar 2022 | Canada
Federal Court Holds Summary Trial Appropriate, Apotex And Pharmascience Will Induce Infringement Of Paliperidone Palmitate Patent
02 Mar 2022 | Canada
Court Permits Amendment Of Patent Record To Remove Inventors And Co-owner
22 Feb 2022 | Canada
Potential Pan-Canadian Formulary: Discussion Paper And Online Questionnaire
22 Feb 2022 | Canada
Upcoming Information Session On Proposed Framework For Potential Pan-Canadian Formulary
05 Jan 2022 | Canada
PMPRB Releases CompassRx Report For 2019/2020
02 Dec 2021 | Canada
Update On Biosimilars In Canada - October 2021
03 Nov 2021 | Canada
Federal Court Approves Litigation Funding Agreement In Proposed Class Proceeding Against Generic Drug Manufacturers
02 Oct 2021 | Canada
PM(NOC) Regulations: Fourth Year Following Major Amendments
02 Oct 2021 | Canada
Quebec Initiating A Shift To Use Of Biosimilar Drugs
19 Jul 2021 | Canada
< 1 2 3 4 >
20%
Very Popular: This author falls within the Top 20% for the below topics and industry categories
Based on Mondaq users readership, this author is ranked as VERY POPULAR in Canada for the topics, user groups and industry sectors listed below*:
Topics
  • Healthcare
Industry
  • Pharmaceuticals & BioTech
* Rankings are based on analysis of the last 12 months of Mondaq readership data across more than 25,000 contributing authors. To be ranked ‘Very Popular’ an author must be in the top 20% of results within the selected criteria.
Contact Details
Toronto
Email Website
1100-150 York Street
Toronto
Canada
Telephone: 1-613-2322486

  © Mondaq® Ltd 1994 - 2022. All Rights Reserved.